v3.26.1
Segment Information (Details)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Reporting [Abstract]            
Number of reportable segments | segment         1  
Segment Reporting [Line Items]            
Revenue from collaborative arrangement $ 0   $ 0   $ 0 $ 65,343
Less:            
Research and development expenses 10,826,549   14,521,407   24,896,656 30,612,309
General and administrative 7,797,973   8,563,112   15,677,859 17,588,082
Total operating expenses 18,624,522   23,084,519   40,574,515 48,200,391
Interest income 363,847   610,638   803,440 1,418,715
Change in fair value of common stock warrant liabilities 13,868,616   (1,878,010)   18,006,319 1,834,862
Gain on investment in affiliated entity 0   776,373   (2,103,688) 1,471,504
Net unrealized gain on available-for-sale equity securities 94,221   759,289   173,298 899,523
Other expense, net (1,714,620)   (703,183)   (2,000,110) (703,665)
Net loss (6,012,458) $ (19,682,798) (23,519,412) $ (19,694,697) (25,695,256) (43,214,109)
INO-3107            
Less:            
Research and development expenses 3,877,243   3,930,320   7,882,534 7,437,662
INO-3112 And Other Immuno-oncology            
Less:            
Research and development expenses 379,056   450,094   744,284 1,134,543
Other programs            
Less:            
Research and development expenses 899,547   1,141,153   1,982,830 1,879,213
Engineering and device-related            
Less:            
Research and development expenses 2,665,853   5,084,662   6,706,969 10,146,472
Stock-based compensation            
Less:            
Research and development expenses 299,295   321,688   574,233 875,082
Other unallocated expenses            
Less:            
Research and development expenses 2,705,555   3,593,490   7,005,806 9,139,337
Reportable Segments            
Segment Reporting [Line Items]            
Revenue from collaborative arrangement 0   0   0 65,343
Less:            
General and administrative 7,797,973   8,563,112   15,677,859 17,588,082
Total operating expenses 18,624,522   23,084,519   40,574,515 48,200,391
Interest income 363,847   610,638   803,440 1,418,715
Change in fair value of common stock warrant liabilities (13,868,616)   1,878,010   (18,006,319) (1,834,862)
Gain on investment in affiliated entity 0   776,373   (2,103,688) 1,471,504
Net unrealized gain on available-for-sale equity securities 94,221   759,289   173,298 899,523
Other expense, net (1,714,620)   (703,183)   (2,000,110) (703,665)
Net loss $ (6,012,458)   $ (23,519,412)   $ (25,695,256) $ (43,214,109)